A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB.

Size: px
Start display at page:

Download "A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB."

Transcription

1 ERJ Express. Published on September 13, 2013 as doi: / A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB. Helen R. Stagg a,b,c, *, Ted Cohen b,d, Mercedes C. Becerra e, Laura F. Anderson c, Ibrahim Abubakar a,c a Research Department of Infection and Population Health, University College London. b Division of Global Health Equity, Brigham and Women's Hospital. c TB Section, Public Health England. d Department of Epidemiology, Harvard School of Public Health. e Department of Global Health and Social Medicine, Harvard Medical School. * Corresponding author: h.stagg@ucl.ac.uk; Research Department of Infection and Population Health, University College London, 4th floor, Mortimer Market Centre, Mortimer Market, London, WC1E 6JB, UK; Telephone: ; Fax: Take home message for social media: Contrasting relationship between the Beijing genotype of Mycobacterium tuberculosis and MDR-TB in England versus Peru. 1 Copyright 2013 by the European Respiratory Society.

2 To the Editor: Described as a template for success by Hanekom et al., the Beijing genotype of Mycobacterium tuberculosis (M. tb) has been associated with hypervirulence, drug resistance, evasion of the Bacillus Calmette-Guérin (BCG) vaccine and differential immunoregulation [1]. The genotype is itself diverse; accordingly the fact that specific traits have been associated with Beijing only in certain settings may be explained by variation in the sub-types that predominate in each. We sought to explore the role that the Beijing genotype has played in the epidemiology of multi-drug resistant tuberculosis (MDR-TB) in two very different epidemiological settings: England and Peru. In the UK nearly three quarters of TB disease occurs amongst migrants, which may result from latent M. tb infections acquired from high-burden countries of origin. Thus the distribution of lineages in the UK reflects a composite of the circulating strains in other nations. Whilst increasing levels of MDR-TB in the UK have triggered understandable concern, only a small fraction of cases are MDR (2011: 1.0%) [2]. In contrast, the Peruvian TB epidemic is relatively home grown and the prevalence of drug resistance is greater (2011: 5.3% MDR) [2]. Our objectives were thus to 1) identify any association between the Beijing genotype and MDR in these two settings and 2) to examine if trends in Beijing might explain changes in the prevalence of MDR-TB over time. The following datasets were used during this study: a) English TB cases: Taken from Public Health England s Enhanced Tuberculosis Surveillance System and Mycobacterial Surveillance Network. England 1-8,859 individuals diagnosed and 24-loci Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR) strain typed between 2010 and Of these, 4,661 had at least first line drug sensitivity data, a minimal 12-loci pre-defined profile [3] and were pulmonary. England MDR-TB cases from which had undergone 24-loci typing. 117 were pulmonary and had the minimal profile. 24-loci typing was not available for non-mdr cases from this period. Susceptibility to rifampicin, isoniazid, ethambutol, pyrazinamide, streptomycin, amikacin, kanamycin, capreomycin, azithromycin, clarithromycin, ciprofloxacin, ofloxacin, moxifloxacin, prothionamide, ethionamide, cycloserine, 4-amino salicylic acid, linezolid, clofazamine and rifabutin had been tested using the proportion or resistance ratio methods. 2

3 b) Peruvian TB cases: Peru sputum positive cases of pulmonary TB recruited from clinical facilities in Lima between 2004 and 2006 extracted from Taype et al. [4]. 229 had been tested for sensitivity to rifampicin, isoniazid, ethambutol and streptomycin, of which 101 (44.1%) were MDR; we note that this figure is much higher than the overall proportion MDR in this setting [2], suggesting that drug susceptibility testing was prioritised for those at highest risk of MDR, consistent with previous Peruvian testing policies. All cases had a complete standard 12-loci profile. Peru 2- Database of 230 cases of pulmonary MDR-TB identified in Lima between 1996 and 2004 [5,6]. Isolates underwent drug susceptibility testing to rifampicin, isoniazid, ethambutol, pyrazinamide, streptomycin, kanamycin, capreomycin, ethionamide, 4-amino salicylic acid and levofloxacin. One individual lacking a complete standard 12-loci profile was excluded, leaving 229. MIRU-VNTRplus was utilised to designate lineages for all four datasets to ensure comparability [7]. Substantial differences in the lineage and sublineage profiles of English (England 1, 4,661 individuals) and Peruvian (Peru 1, 229 individuals) pulmonary TB cases were apparent (χ 2 test of independence p-value <0.001). The vast majority of Peruvian cases were of the Euro-American lineage (92.6%; 212/229), with LAM the majority sublineage (48.1%; 102/212). The remainder of cases were nearly all Beijing (6.6%; 15/229). In contrast, English cases comprised a variety of lineages consistent with their multinational origins: 51.8% Euro-American (2,412/4,661), 28.6% Delhi-CAS (1,335/4,661), 9.2% EAI (429/4,661), 8.3% Beijing (392/4,661). The Euro-American sublineages seen were also diverse. Restricting our analysis to MDR cases again revealed very different profiles between Peru and England (p-value <0.001). Peruvian cases (Peru 2, 229 individuals) were dominated by the Euro-American lineage (93.9%; 215/229), 56.3% of which was the LAM sublineage (121/215). Regression modelling of Peru 1 to explore the relationship between MDR and M. tb lineage showed no association (Beijing crude odds ratio (OR) 1.10 (95% confidence interval (CI) ), Wald p-value 0.86; Euro-American baseline). In stark contrast to the overall distribution of lineages, among English MDR cases (England 1) the proportion Beijing increased to 47.4% (36/76). Regression modelling revealed a strong positive association between Beijing and MDR among English pulmonary cases (crude OR ( ), <0.005; adjusted OR 9.53 ( ), <0.005; Euro-American baseline; England 1; models excluded non-m. tb cases and those with missing data). Age, gender, a composite social risk factor variable (homelessness, imprisonment, drug/alcohol abuse), country of birth, ethnic 3

4 group and previous diagnosis were adjusted for in the latter; this could not be done for Peru 1 as these variables were not available. We also tested whether Beijing was enriched among strains with resistance to a greater number of drugs (figure 1a). Pre-MDR-TB (pre-mdr) was defined as resistance to either, but not both, isoniazid and rifampicin. Pre-extensively drug resistant (pre-xdr) cases were MDR plus resistant to either a fluoroquinolone or a second-line injectable. Beijing was enriched from pre-mdr to XDR cases in the English data (Pearson s correlation coefficient p trend Beijing versus non-beijing <0.005; England 1). This could be specifically observed among non-uk born, but not UK born, cases (data not shown). No trend was seen in the Peruvian data (p trend 0.76; Peru 1 and Peru 2). Further analysis to determine whether the association has changed over time indicated a recent increase in the proportion of cases caused by Beijing (p trend <0.005) (figure 1b; England 1 and England 2). Our analysis suggests that the Beijing genotype plays a different role in the current epidemiology of MDR-TB in England and Peru. In England, the observed association likely reflects rising importation of resistant strains, rather than the development of resistance within the UK. In Peru there is likely to be a similarly high prevalence of MDR among all genotypes, potentially explaining why we did not observe an association. Interestingly, a recent paper by Iwamoto et al. suggests that the overall prevalence of Beijing has increased in Peru over the last decade, but the proportion of Beijing strains that are MDR has decreased [8]. We utilised available datasets from studies undertaken at different times with variable designs, thus some interpretative caution is required. For example, Peru 2 recruited from households with more than one pulmonary MDR cases, and thus could have oversampled clustered cases. However, the similarity of the lineage profiles of Peru 2 with Peru 1, which was not collected through such means, suggests this effect is limited. English cases were tested for resistance to a wider range of drugs than the Peruvian cases, thus the no known resistance category is not strictly comparable between the two datasets. Nevertheless, only 1.3% of England 1 was resistant to drugs not tested within Peru 1. Molecular epidemiological surveillance and addressing and preventing resistance have been highlighted as vital for TB elimination by the European Respiratory Society [9,10]. We demonstrate within this study how the tools of the former could be vital to aid the latter: within Peru where the MDR epidemic could worsen should fitter drug resistant Beijing strains evolve or enter the country, and within the UK where the lineage profile is highly dynamic. 4

5 ACKNOWLEDGEMENTS We acknowledge our utilisation of the published data of Taype et al. [4]. Our study made use of the MIRU-VNTRplus database website ( developed by D. Harmsen, S. Niemann, P. Supply and T. Weniger. FOOTNOTES HRS acknowledges the support of the European Respiratory Society, Fellowship STRTF We also acknowledge Public Health England s Strain Typing Project for funding the strain typing of the English data. IA is funded through a NIHR Senior Research Fellowship. REFERENCES 1. Hanekom M, Gey van Pittius NC, McEvoy C, Victor TC, Van Helden PD, Warren RM. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis (Edinb ) 2011;91(6): World Health Organisation. Global tuberculosis control: WHO report World Health Organisation; Savine E, Warren RM, van der Spuy GD, Beyers N, Van Helden PD, Locht C, et al. Stability of variable-number tandem repeats of mycobacterial interspersed repetitive units from 12 loci in serial isolates of Mycobacterium tuberculosis. J Clin Microbiol 2002;40(12): Taype CA, Agapito JC, Accinelli RA, Espinoza JR, Godreuil S, Goodman SJ, et al. Genetic diversity, population structure and drug resistance of Mycobacterium tuberculosis in Peru. Infect Genet Evol 2012;12(3): Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011;377(9760): Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Communitybased therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348(2): Allix-Beguec C, Harmsen D, Weniger T, Supply P, Niemann S. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008;46(8): Iwamoto T, Grandjean L, Arikawa K, Nakanishi N, Caviedes L, Coronel J, et al. Genetic diversity and transmission characteristics of Beijing family strains of Mycobacterium tuberculosis in Peru. PLoS One 2012;7(11):e Blasi F, Reichman LB, Migliori GB. Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe. Eur Respir J 2012;40(4):

6 10. Diel R, Loddenkemper R, Zellweger JP, Sotgiu G, D'Ambrosio L, Centis R, et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur Respir J

7 Figure 1. The Beijing genotype is enriched with increasing drug resistance in English cases and may be increasingly represented among MDR cases over time. a) The Beijing genotype is enriched with increasing drug resistance in English (England 1) (p trend <0.005 Beijing versus non-beijing), but not Peruvian (Peru 1, Peru 2), pulmonary TB cases. b) Lineages of English pulmonary MDR-TB cases (England 1, England 2), presented by year of diagnosis. The proportion of cases associated with the Beijing genotype may be increasing with time in the latter years. CAS- Central Asian, EAI- East-Africa Indian, TB- tuberculosis, *- 24-loci MIRU-VNTR typing was not undertaken between 2008 and a) England 1 Peru 1 Peru 2 b) * * England 1 England 2

Annual surveillance report 2015

Annual surveillance report 2015 Annual surveillance report 215 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing

Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing Laura F Anderson, Surinder Tamne, Timothy Brown, John

More information

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA January 2016 Summary This report describes the geographical and temporal distribution of multidrug-resistant (MDR) tuberculosis

More information

Tuberculosis in South West Centre: Annual review (2014 data) Data from 2000 to 2014

Tuberculosis in South West Centre: Annual review (2014 data) Data from 2000 to 2014 Tuberculosis in South West Centre: Annual review (2014 data) Data from 2000 to 2014 2 About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing,

More information

Tuberculosis in Wales Annual Report 2015

Tuberculosis in Wales Annual Report 2015 Tuberculosis in Wales Annual Report 2015 Author: Communicable Disease Surveillance Centre Date: 10/03/2016 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This annual

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment

More information

Tuberculosis in the UK. Report on tuberculosis surveillance in the UK 2010

Tuberculosis in the UK. Report on tuberculosis surveillance in the UK 2010 Tuberculosis in the UK Report on tuberculosis surveillance in the UK 2010 Authors and contributors Main authors Dr Laura Anderson, Jonathan Moore, Dr Michelle Kruijshaar, Debora Pedrazzoli, Louise Bradshaw,

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

Disconnect between sputum neutrophils and other measures of airway inflammation in asthma

Disconnect between sputum neutrophils and other measures of airway inflammation in asthma AGORA RESEARCH LETTERS Disconnect between sputum neutrophils and other measures of airway inflammation in asthma To the Editor: Asthma heterogeneity has been described by the nature and intensity of granulocytic

More information

Tuberculosis in Chicago 2007

Tuberculosis in Chicago 2007 City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease

More information

Annual surveillance report 2016

Annual surveillance report 2016 Annual surveillance report 216 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Tuberculosis in Wales Annual Report 2013

Tuberculosis in Wales Annual Report 2013 Tuberculosis in Wales Annual Report 2013 Author: Communicable Disease Surveillance Centre Date: 16/12/13 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This report

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA SURVEILLANCE REPORT Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA March 2017 Summary This report describes the geographical and temporal distribution of multidrug-resistant

More information

Tuberculosis in Wales Annual Report 2014

Tuberculosis in Wales Annual Report 2014 Tuberculosis in Wales Annual Report 2014 Author: Communicable Disease Surveillance Centre Date: 20/03/2015 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This report

More information

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first

More information

Tuberculosis in the UK 2013 report

Tuberculosis in the UK 2013 report Tuberculosis in the UK 2013 report About Public Health England Public Health England s mission is to protect and improve the nation s health and to address inequalities through working with national and

More information

Tuberculosis in London Annual review (2015 data) Data from 2000 to 2015

Tuberculosis in London Annual review (2015 data) Data from 2000 to 2015 Tuberculosis in London Annual review (2015 data) Data from 2000 to 2015 About Public Health England Public Health England exists to protect and improve the nation s health and wellbeing, and reduce health

More information

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

The emerging threat of multidrug resistant TB: Global and local challenges and solutions Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR

More information

Transmission of MDR and XDR Tuberculosis in Shanghai, China

Transmission of MDR and XDR Tuberculosis in Shanghai, China Transmission of MDR and XDR Tuberculosis in Shanghai, China Ming Zhao 1,2., Xia Li 2., Peng Xu 1,2, Xin Shen 1, Xiaohong Gui 1, Lili Wang 1, Kathryn DeRiemer 3, Jian Mei 1 *, Qian Gao 2 * 1 Department

More information

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948

More information

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending EDITORIAL TUBERCULOSIS Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending Max Salfinger 1 and Giovanni Battista Migliori 2 Affiliations: 1 Dept of Medicine, National

More information

Tuberculosis in Wales Annual Report 2016

Tuberculosis in Wales Annual Report 2016 Tuberculosis in Wales Annual Report 2016 Author: Communicable Disease Surveillance Centre Date: 03/11/2016 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This annual

More information

TB trends and TB genotyping

TB trends and TB genotyping Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

2016 Annual Tuberculosis Report For Fresno County

2016 Annual Tuberculosis Report For Fresno County 206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis

More information

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Molecular Epidemiology of Tuberculosis Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Overview TB transmission and pathogenesis Genotyping methods Genotyping for clinical management

More information

Short Course Treatment for MDR TB

Short Course Treatment for MDR TB Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize

More information

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza

More information

Tuberculosis in South East Centre: Annual review (2015 data) Data from 2000 to 2015

Tuberculosis in South East Centre: Annual review (2015 data) Data from 2000 to 2015 Tuberculosis in South East Centre: Annual review (2015 data) Data from 2000 to 2015 Tuberculosis in South East Centre (2015) About Public Health England Public Health England exists to protect and improve

More information

Sputum culture results to monitor MDR-TB patients during treatment: How many do we

Sputum culture results to monitor MDR-TB patients during treatment: How many do we JCM Accepts, published online ahead of print on 5 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.02837-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 Sputum culture

More information

APSR RESPIRATORY UPDATES

APSR RESPIRATORY UPDATES APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient

More information

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Human Journals Review Article August 2016 Vol.:1, Issue:3 All rights are reserved by Mr. Suraj Narayan Mali et al. Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Keywords: Totally Drug-resistant

More information

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)

More information

TUBERCULOSIS IN NEW ZEALAND ANNUAL REPORT 2015

TUBERCULOSIS IN NEW ZEALAND ANNUAL REPORT 2015 TUBERCULOSIS IN NEW ZEALAND ANNUAL REPORT 2015 PREPARED FOR: CLIENT REPORT No: PREPARED BY: Ministry of Health FW17009 PUBLISHED: September 2018 Health Intelligence Team, Health and Environment Group Institute

More information

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Eur Respir J 2009; 33: 1085 1094 DOI: 10.1183/09031936.00155708 CopyrightßERS Journals Ltd 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB K. Kliiman and

More information

The authors assessed drug susceptibility patterns

The authors assessed drug susceptibility patterns Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division

More information

Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data

Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data ORIGINAL ARTICLE TUBERCULOSIS Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data Catherine M. Smith 1, Helen Maguire 2,3, Charlotte Anderson 2,

More information

TUBERCULOSIS IN NEW ZEALAND 2014

TUBERCULOSIS IN NEW ZEALAND 2014 SURVEILLANCE REPORT TUBERCULOSIS IN NEW ZEALAND 2014 Prepared as part of a Ministry of Health contract for scientific services by the Health Intelligence Team, Institute of Environmental Science and Research

More information

Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis

Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis REVIEW 10.1111/j.1469-0691.2011.03577.x Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis W. Sougakoff National Reference Centre for Mycobacteria (CNR-MyRMA), Laboratoire

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

HA Convention 2016 : Special Topic Session 3 May 2016

HA Convention 2016 : Special Topic Session 3 May 2016 HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis

More information

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Evolution of XDR-TB in KwaZulu-Natal A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Drug resistance among culture positive TB cases by South African

More information

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of

More information

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic The Journal of International Medical Research 2010; 38: 1156 1163 [first published online as 38(3) 26] Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside

More information

DRUG-RESISTANT TUBERCULOSIS

DRUG-RESISTANT TUBERCULOSIS DRUG-RESISTANT TUBERCULOSIS WHAT HAVE WE LEARNED? PAUL FARMER, MD, PHD HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL WORKSHOP ON MDR-TB BEIJING, PEOPLES REPUBLIC

More information

Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data

Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data The Journal of Infectious Diseases MAJOR ARTICLE Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data Jonathan L. Zelner, 1 Megan B. Murray, 2

More information

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant

More information

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka

More information

Role of RNTCP in the management MDR-TB

Role of RNTCP in the management MDR-TB Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A

More information

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Chapter 1 Overview of Tuberculosis Epidemiology in the United States Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States... 3 TB Disease Trends in the United

More information

Management of Drug-resistant Tuberculosis (DR-TB)

Management of Drug-resistant Tuberculosis (DR-TB) Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical

More information

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility

More information

Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2008

Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2008 Tuberculosis in the UK Annual report on tuberculosis surveillance in the UK 2008 Acknowledgements This report was prepared by the Tuberculosis Section, Health Protection Agency Centre for Infections. This

More information

Global TB Burden, 2016 estimates

Global TB Burden, 2016 estimates TUBERCULOSIS EPIDEMIOLOGY LOCAL, STATE, NATIONAL, GLOBAL Office of Communicable Disease Epidemiology Global TB Burden, 216 estimates Total TB Estimated number of TB cases 1.4 million 14 per 1, Estimated

More information

PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA

PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA DN Magana-Arachchi 1, AJ Perera 1, V Senaratne 2 and NV Chandrasekharan

More information

Tuberculosis in North East England: Annual review (2015 data) Data from 2000 to 2015

Tuberculosis in North East England: Annual review (2015 data) Data from 2000 to 2015 Tuberculosis in North East England: Annual review (2015 data) Data from 2000 to 2015 Tuberculosis in North East Centre (2015) About Public Health England Public Health England exists to protect and improve

More information

Marcos Burgos, MD has the following disclosures to make:

Marcos Burgos, MD has the following disclosures to make: Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures

More information

New Frontiers: Innovation and Access

New Frontiers: Innovation and Access 8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB

More information

Children as Sentinels for Transmission and Policy Response Mercedes Becerra, ScD

Children as Sentinels for Transmission and Policy Response Mercedes Becerra, ScD Children as Sentinels for Transmission and Policy Response Mercedes Becerra, ScD Associate Professor, Harvard Medical School, Boston, MA, USA TB Specialist, Partners In Health, Boston, MA, USA Overview

More information

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition

More information

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype

Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype ORIGINAL ARTICLE Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype Manish Pareek, 1,2,3 Jason Evans, 4 John Innes, 5 Grace Smith, 4 Suzie Hingley-Wilson, 1 Kathryn E

More information

Treatment outcomes of multidrug-resistant tuberculosis in Switzerland

Treatment outcomes of multidrug-resistant tuberculosis in Switzerland Published 4 December 04, doi:0.444/smw.04.405 Cite this as: Swiss Med Wkly. 04;44:w405 Treatment outcomes of multidrug-resistant tuberculosis in Switzerland Peter Helbling a, Ekkehardt Altpeter a, Jean-Marie

More information

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

A study on pre-xdr & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India

A study on pre-xdr & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India Indian J Med Res 143, March 2016, pp 341-347 DOI:10.4103/0971-5916.182625 A study on pre-xdr & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case

More information

Tuberculosis in NSW,

Tuberculosis in NSW, EPIREVIEW Tuberculosis in NSW, 2003 2007 Bridget A. O Connor, Lindy L. Fritsche, Amanda J. Christensen and Jeremy M. McAnulty Communicable Diseases Branch, NSW Department of Health Tuberculosis (TB) has

More information

Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation

Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation ORIGINAL ARTICLE TUBERCULOSIS Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation Dominik Zenner 1,2,3, Miranda G. Loutet

More information

Ibrahim Abubakar, MBBS, MSc, PhD, FFPH

Ibrahim Abubakar, MBBS, MSc, PhD, FFPH Ibrahim Abubakar, MBBS, MSc, PhD, FFPH Head of Section / Consultant Epidemiologist Tuberculosis Section HPA Centre for Infections Colindale London UK Outline TB epidemiological situation UK data collection

More information

Transmission of multidrug-resistant tuberculosis in a low-incidence setting, Switzerland, 2006 to 2012

Transmission of multidrug-resistant tuberculosis in a low-incidence setting, Switzerland, 2006 to 2012 Research articles Transmission of multidrug-resistant in a low-incidence setting, Switzerland, 2006 to 2012 A Somoskovi (asomoskoevi@imm.uzh.ch) 1, P Helbling 2, V Deggim 1, R Hömke 1, C Ritter 1, E C

More information

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH. The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,

More information

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana

More information

Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines

Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines Sia et al. BMC Infectious Diseases 2013, 13:571 RESEARCH ARTICLE Open Access Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines

More information

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa Tropical Medicine and International Health doi:10.1111/j.1365-3156.2010.02590.x volume 15 no 10 pp 1179 1184 october 2010 Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South

More information

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine

More information

A review of Outcomes of Treatment among 29 cases of Extensively Drug Resistant Tuberculosis in Johannesburg

A review of Outcomes of Treatment among 29 cases of Extensively Drug Resistant Tuberculosis in Johannesburg A review of Outcomes of Treatment among 29 cases of Extensively Drug Resistant Tuberculosis in Johannesburg Ntambwe Malangu 1 and Mame Dieynaba DIA-DIOP 2 Abstract The purpose of this study was to describe

More information

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1 XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma Pag. 1 TB estimated incidence in EUR, 2004 Russian Fed. 12 th among the 22 TB high-burden

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University

April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University MDR-TB, XDR-TB, and TDR-TB. Is this April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University MDR XDR TDR What s in a name? Dr Dick Menzies Le Chest (McGill, Montreal) 1 Disclaimer I

More information

Tuberculosis in Chicago 2006

Tuberculosis in Chicago 2006 Chicago Department of Public Health May 27 Communicable Disease Information Tuberculosis in Chicago 26 City of Chicago Richard M. Daley, Mayor Department of Public Health Terry Mason, MD, FACS Commissioner

More information

Annual Epidemiological Report

Annual Epidemiological Report Annual Epidemiological Report March 2018 National TB surveillance in Ireland, 2017 Key Facts 321 TB cases were notified to HPSC corresponding to a crude incidence rate (CIR) of 6.7 HSE East reported the

More information

Online Annexes (5-8)

Online Annexes (5-8) 2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings

More information

TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks

TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 1 TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 2 Page 1 4 NHS Lothian Infection Prevention and Control Study Day On

More information

Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli

Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli CHEST Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli Original Research Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran Ali Akbar Velayati,

More information

Annex 2. GRADE glossary and summary of evidence tables

Annex 2. GRADE glossary and summary of evidence tables WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for

More information

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis

More information

2014 Annual Report Tuberculosis in Fresno County. Department of Public Health

2014 Annual Report Tuberculosis in Fresno County. Department of Public Health 214 Annual Report Tuberculosis in Fresno County Department of Public Health www.fcdph.org Tuberculosis (TB) is a common communicable disease caused by the bacterium Mycobacterium tuberculosis and occasionally

More information

Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China

Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China Qi Wang 1., Susanna K. P. Lau 2., Fei Liu 1., Yanlin Zhao 3,

More information

Multidrug-resistant tuberculosis in children

Multidrug-resistant tuberculosis in children Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten

More information

Background paper number 5

Background paper number 5 Background paper number 5 Assessing the quality and coverage of surveillance data in the UK: how is it done and how can HPA help to develop the Task Force framework for assessment of surveillance data,

More information

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Journal of Microbiology Research 2014, 4(6A): 25-31 DOI: 10.5923/s.microbiology.201401.04 Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Asho Ali Department of Biology, King Abdul Aziz

More information